| Foreword |
|
xi | |
| Preface |
|
xiii | |
| Acknowledgements |
|
xvii | |
|
Chapter 1 Infectious diseases: a historical documentary |
|
|
1 | (24) |
|
The origins of infectious diseases |
|
|
3 | (2) |
|
Viruses and cells: early origins |
|
|
5 | (3) |
|
Susceptibility to pathogenic viruses |
|
|
8 | (1) |
|
Antibiotic resistance and its origins |
|
|
9 | (3) |
|
Epidemics, pandemics, and survival |
|
|
12 | (3) |
|
Understanding how infectious diseases spread |
|
|
15 | (1) |
|
The beginnings of epidemiological thinking |
|
|
16 | (2) |
|
Epidemiological principles in infectious disease |
|
|
18 | (3) |
|
|
|
21 | (4) |
|
Chapter 2 The scourge of smallpox: variolation, vaccination, and Edward Jenner |
|
|
25 | (28) |
|
|
|
25 | (5) |
|
Virus DNA as a historical record |
|
|
30 | (3) |
|
|
|
33 | (2) |
|
The origins and spread of inoculation |
|
|
35 | (4) |
|
Inoculation in Europe: the role of dogma and prejudice |
|
|
39 | (2) |
|
The demise of smallpox inoculation and rise of the vacca |
|
|
41 | (6) |
|
Earlier claims for cowpox vaccination |
|
|
47 | (1) |
|
|
|
48 | (1) |
|
|
|
49 | (4) |
|
Chapter 3 Smallpox vaccination in the 19th century: obstinacy versus pragmatism |
|
|
53 | (20) |
|
Early medical doctrine: the four "humors" |
|
|
53 | (2) |
|
Disease prevention: inoculation versus vaccination in Europe |
|
|
55 | (10) |
|
The North American experience |
|
|
65 | (3) |
|
Great Britain---no better, no worse |
|
|
68 | (2) |
|
|
|
70 | (3) |
|
Chapter 4 The biological origins of infection unveiled |
|
|
73 | (22) |
|
The backcloth of early experimental observation |
|
|
73 | (1) |
|
Anthrax: a disease reveals its causative agent |
|
|
74 | (1) |
|
The birth of Pasteur's germ theory |
|
|
75 | (3) |
|
Proving causation was not trivial |
|
|
78 | (4) |
|
Rabies meets "the prepared mind" |
|
|
82 | (6) |
|
The importance of strong microbiology in identifying the causes of infection |
|
|
88 | (2) |
|
Tuberculosis and its cause |
|
|
90 | (2) |
|
|
|
92 | (1) |
|
|
|
93 | (2) |
|
Chapter 5 Cholera, plague, typhoid, and paratyphoid: a cautious start to a vaccine revolution |
|
|
95 | (24) |
|
Cholera meets a rigorous analyst |
|
|
95 | (6) |
|
|
|
101 | (4) |
|
|
|
105 | (10) |
|
|
|
115 | (4) |
|
Chapter 6 Diphtheria and tetanus: the discovery of passive immunization |
|
|
119 | (34) |
|
The diphtheria microorganism identified |
|
|
123 | (8) |
|
The development of anti-diphtheria therapy and the role of tetanus research |
|
|
131 | (6) |
|
The dawn of passive immunization |
|
|
137 | (4) |
|
Serum therapy arrives on the world stage |
|
|
141 | (3) |
|
A diphtheria vaccine emerges |
|
|
144 | (2) |
|
From passive immunotherapy to active vaccines |
|
|
146 | (2) |
|
Diphtheria, tetanus, and pertussis vaccination today |
|
|
148 | (1) |
|
|
|
149 | (4) |
|
Chapter 7 The tuberculosis roller coaster: vaccines and antibiotics |
|
|
153 | (28) |
|
|
|
160 | (6) |
|
Tuberculosis and the impact of chemical intervention |
|
|
166 | (8) |
|
The persistent treatment dilemma |
|
|
174 | (3) |
|
|
|
177 | (4) |
|
Chapter 8 Viruses: epic challenges for vaccinology |
|
|
181 | (28) |
|
|
|
181 | (3) |
|
|
|
184 | (10) |
|
The discovery of bacterial viruses |
|
|
194 | (2) |
|
|
|
196 | (2) |
|
The illusive virus nature revealed |
|
|
198 | (5) |
|
|
|
203 | (2) |
|
Vaccine effects on virus and bacterial fitness |
|
|
205 | (1) |
|
|
|
206 | (3) |
|
Chapter 9 Some tropical diseases: the flaviviruses |
|
|
209 | (46) |
|
|
|
209 | (12) |
|
The yellow fever vaccine today |
|
|
221 | (2) |
|
|
|
223 | (5) |
|
The dengue virus discovery |
|
|
228 | (3) |
|
Dengue vaccine development and the unusual immunology of multiple infections |
|
|
231 | (2) |
|
|
|
233 | (1) |
|
Japanese encephalitis virus |
|
|
234 | (2) |
|
A Japanese encephalitis vaccine emerges |
|
|
236 | (4) |
|
|
|
240 | (1) |
|
|
|
240 | (6) |
|
|
|
246 | (2) |
|
|
|
248 | (1) |
|
|
|
249 | (6) |
|
Chapter 10 Influenza virus: an evolving chameleon |
|
|
255 | (36) |
|
|
|
255 | (2) |
|
|
|
257 | (8) |
|
The Spanish `flu and the search for its cause' |
|
|
265 | (9) |
|
Influenza pandemics in the modern era |
|
|
274 | (7) |
|
The H/N "Pandora's box" and vaccine advances |
|
|
281 | (6) |
|
|
|
287 | (4) |
|
Chapter 11 The Polio virus: its conquest amid inflamed debate and controversy |
|
|
291 | (42) |
|
The history of polio virus infection |
|
|
291 | (6) |
|
The Scandinavian experience |
|
|
297 | (2) |
|
The poliomyelitis virus discovered |
|
|
299 | (6) |
|
The pathogenesis of poliomyelitis defined |
|
|
305 | (1) |
|
|
|
306 | (7) |
|
Polio vaccine trials: triumph and alarm bells |
|
|
313 | (5) |
|
Live attenuated virus vaccines: the "catch up" race |
|
|
318 | (7) |
|
Vaccine safety concerns and their resolution |
|
|
325 | (1) |
|
The race to eliminate the polio virus |
|
|
326 | (2) |
|
|
|
328 | (1) |
|
|
|
329 | (4) |
|
Chapter 12 Measles, mumps, and rubella: vaccination, mortality, and uncertainty |
|
|
333 | (36) |
|
Measles virus and its history |
|
|
333 | (6) |
|
A measles vaccine emerges |
|
|
339 | (3) |
|
The effect of vaccines on measles incidence |
|
|
342 | (2) |
|
Mumps virus and its history |
|
|
344 | (5) |
|
Attenuated viruses become the dominant mumps vaccine |
|
|
349 | (3) |
|
Rubella virus: a wolf in sheep's clothing |
|
|
352 | (4) |
|
Isolation of rubella virus and the vaccine trail |
|
|
356 | (4) |
|
The combination vaccines of measles, mumps, rubella |
|
|
360 | (5) |
|
|
|
365 | (4) |
|
Chapter 13 Filoviruses: modern solutions to life-threatening infections |
|
|
369 | (26) |
|
Introduction and recent history |
|
|
369 | (4) |
|
The origins of filoviruses |
|
|
373 | (2) |
|
Prevention the only option when no cure exists |
|
|
375 | (1) |
|
|
|
376 | (12) |
|
The vaccine situation today and the role of passive immunotherapy |
|
|
388 | (4) |
|
|
|
392 | (1) |
|
|
|
392 | (3) |
|
Chapter 14 Immunological challenges of the "new" infections: corona viruses |
|
|
395 | (56) |
|
|
|
395 | (3) |
|
A new viral pathogen arrives |
|
|
398 | (2) |
|
The SARS disease: its origins and its causative agent |
|
|
400 | (6) |
|
The way out: vaccines to SARS-CoV |
|
|
406 | (2) |
|
Nonsemper erit aestas---MERS attack |
|
|
408 | (5) |
|
The stuttering path to a MERS-CoV vaccine |
|
|
413 | (6) |
|
SARS-CoV2---the darker side of coronaviridae |
|
|
419 | (3) |
|
|
|
422 | (6) |
|
Pandemic models and the vaccine solutions for COVID19 |
|
|
428 | (13) |
|
COVID19 and the role of passive antibody therapy |
|
|
441 | (3) |
|
Interim epilogue: vaccine nationalism and effective use of global resources |
|
|
444 | (1) |
|
|
|
445 | (6) |
|
Chapter 15 Vaccines are not always perfect: adverse effects and their clinical impact |
|
|
451 | (16) |
|
Vaccine safety evaluation |
|
|
456 | (1) |
|
The other "substances" in vaccines! |
|
|
457 | (5) |
|
COVID19 vaccines and safety |
|
|
462 | (3) |
|
|
|
465 | (2) |
|
Chapter 16 Vaccination and freedom of choice: the individual and the population |
|
|
467 | (8) |
|
Religious and ethical grounds for vaccine hesitancy |
|
|
468 | (1) |
|
The safety question: hesitancy amid misinformation |
|
|
469 | (3) |
|
The genuine concerns of vaccination |
|
|
472 | (2) |
|
|
|
474 | (1) |
| Glossary |
|
475 | (14) |
| Index |
|
489 | |
Biežāk uzdotie jautājumi par e-grāmatām